January, 2022 - Bluejay Therapeutics

2022 Global IR @ JPM Virtual Demo Day Tickets, Wed, Jan 19, 2022 at 7:00 pm | Eventbrite

Bluejay Therapeutics will present in the 2nd annual Global IR @ JPM (Jan. 19-20 EST).

Bluejay Therapeutics’ presentation would be delivered live, via Zoom, as part of our Day 2 Global Biotech track (7:30-9:30 p.m. EST on Jan. 20).

Since 1993, BioCentury Inc. has been internationally recognized as the leading provider of value-added information, analysis and data for biotechnology and pharmaceutical companies, investors, academia and government on the strategic issues essential to the formation, development and sustainability of life science ventures. Register

Bluejay Therapeutics to Present at the 2nd Global IR @ JPM Conference

SAN MATEO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) — BlueJay Therapeutics, a private biopharmaceutical company focused on cures for infectious diseases, today announced that chairman and chief executive officer, Dr. Keting Chu, M.D., Ph.D., will present at the 2^nd Global IR @ JPM Conference on Thursday, January 20, 2022 in the biotech track to be held 7:30 – 9:30 p.m. ET.

Dr. Chu will provide an overview of the company, including BlueJay’s two therapeutic approaches with potential high rate of functional cure for HBV infections — its best-in-class anti-HBsAg monoclonal antibody approach and novel, first-in-class HBsAg inhibitor program — its preeminent management team with a proven track record in anti-infectives, strong patent position and backing by top healthcare investors.

To access the live webcast, please visit https://www.eventbrite.com/e/2022-global-ir-jpm-virtual-demo-day-tickets-220953005387.

About BlueJay Therapeutics
BlueJay Therapeutics is a private biopharmaceutical company focused on cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. BlueJay is advancing two innovative approaches with the potential for high rate of functional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients. For more information on BlueJay, please visit the company’s website at www.bluejaytx.com.

Contact:
Alexandra Santos
asantos@wheelhouselsa.com

Keting Chu

Founder, Chief Executive Officer and Chairman of the Board

Dr. Keting Chu is an experienced biotech executive, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development in both large and small biotechnology companies and venture investments.

Prior to founding Bluejay, Keting was a Partner and a Venture partner at LYFE Capital. Working with the team in Lyfe capital, Keting helped to close $550M Lyfe Capital Fund III and invested in Ansun Biopharm, Pliant Therapeutics and Tempest Therapeutics. Pliant and Tempest went IPO in NASDAQ successfully in 2020 and 2021. Keting was previously a venture partner in Apple Tree Partners briefly. Before joining Apple Tree Partners, Keting spent five years as VP, Research TAP at The Leukemia and Lymphoma Society (LLS). There she was responsible for venture philanthropy, also known as the Therapy Acceleration program. At LLS, Keting led the investment into Celator, Stemline, Constellation, Affimed, ArgenX, Kite Pharma, Kiadis, OncoPep, Valor and a number of projects in academic institutions with the focus on proof-of-concept (POC) studies in patients. Three of the nine companies received “Breakthrough” designation by the FDA in 2016 after positive proof-of-concept studies. Celator was acquired by Jazz Pharma for $1.5B, Kite by Gilead for $12B and Stemline by Menarini for $677M. Three NDAs, by Celator, Kite and Stemline, were approved by the US FDA successfully. Prior to LLS, Keting was the CEO of Mission Therapeutics and the Co-Founder, President and CEO of DigitAB, Inc. and BioCubed Corporation. For her first startup company, Five Prime Therapeutics, Keting was Vice President of Biology and Head of R&D where she built the R&D strategy and team, established the technology platform and generated a product pipeline. Prior to Five Prime, Keting was the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation, where she engaged in preclinical and clinical developments of protein, DNA-based, and small molecule therapeutics for cancer and inflammatory diseases. Three cancer therapeutic antibodies that keting led the team from discovery to phase I clinical trials are in phase II and III testing now.

Keting received her MD in Sun Yat-Sen Medical University where she specialized in infectious diseases in China, and Ph.D. in Microbiology and Immunology at University of California at San Francisco (UCSF). She also conducted her postdoctoral training at Cardiovascular Research Institute at UCSF.